Condition: Secondary Hemophagocytic Lymphohistiocytosis (sHLH) · Sponsor: Electra Therapeutics Inc.
Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocytosis (sHLH) is the most common form of this disease and is typically associated with several other clinical conditions (eg, malignancy associated HLH (mHLH), infection, or autoimmune disease). ELA026 is a fully human immunoglobulin G1 (IgG1) signal regulatory protein (SIRP)-directed monoclonal antibody designed to deplete the myeloid and T cells driving the inflammation. The purpose of this study is to assess the safety, efficacy pharmacokinetics and pharmacodynamics of ELA026 in participants with sHLH.
This description comes directly from the study's public registry record.
Clinical Trials · Please email · clinicaltrials@electra-therapeutics.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham School of Medicine | Birmingham, Alabama, United States | Recruiting |
| Phoenix Children's Hospital | Phoenix, Arizona, United States | Active Not Recruiting |
| University of California, Los Angeles | Los Angeles, California, United States | Active Not Recruiting |
| MedStar Georgetown University Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Johns Hopkins All Children's Hospital | St. Petersburg, Florida, United States | Recruiting |
| Children's Healthcare of Atlanta - Center for Advanced Pediatrics | Atlanta, Georgia, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| National Institute of Allergy and Infectious Diseases (NIAID) | Rockville, Maryland, United States | Recruiting |
| Columbia University | New York, New York, United States | Recruiting |
| Cornell University | New York, New York, United States | Recruiting |
| Hackensack University Medical Center | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
+ 29 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05416307